# S 81694 Plus Paclitaxel in Metastatic Breast Cancer

> **NCT03411161** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Combination therapy (S81694 + paclitaxel) phase I
- **DRUG:** Paclitaxel
- **DRUG:** Combination therapy (S81694 + paclitaxel) phase II

## Key facts

- **NCT ID:** NCT03411161
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2020-06-08
- **Final completion:** 2020-06-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03411161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03411161, "S 81694 Plus Paclitaxel in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03411161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*